<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:5pt Arial, sans-serif; }
 .font1 { font:6pt Arial, sans-serif; }
 .font2 { font:7pt Arial, sans-serif; }
 .font3 { font:8pt Arial, sans-serif; }
 .font4 { font:9pt Arial, sans-serif; }
 .font5 { font:10pt Arial, sans-serif; }
 .font6 { font:11pt Arial, sans-serif; }
 .font7 { font:14pt Arial, sans-serif; }
 .font8 { font:16pt Arial, sans-serif; }
 .font9 { font:23pt Arial, sans-serif; }
 .font10 { font:10pt Times New Roman, serif; }
 .font11 { font:31pt Times New Roman, serif; }

</style>
</head>
<body>
<div>
<p><span class="font11">J.P. Morgan</span></p>
</div><br clear="all">
<div>
<p><span class="font4">Completed 06 Sep 2016 06:29 PM HKT</span></p>
<p><span class="font4">Disseminated 07 Sep 2016 09:27 PM HKT</span></p>
<p><span class="font5">Asia Pacific Equity Research</span></p>
<p><span class="font4">07 September 2016</span></p>
</div><br clear="all">
<div><a name="caption1"></a>
<h2><a name="bookmark0"></a><span class="font9" style="font-weight:bold;"><a name="bookmark1"></a>Sinopharm</span></h2>
<p><span class="font7">Largest pharma distributor continue to expand; Neutral on rich valuation</span></p>
</div><br clear="all">
<div>
<h6><a name="bookmark2"></a><span class="font8" style="font-weight:bold;"><a name="bookmark3"></a>Neutral</span></h6>
<p><span class="font4">Previous: Not Rated</span></p>
<p><span class="font4" style="font-weight:bold;">1099.HK, 1099 HK</span></p>
<p><span class="font4">Price: HK$40.55</span></p>
</div><br clear="all">
<div>
<p><span class="font4" style="font-weight:bold;">Price Target: HK$44.00</span></p>
</div><br clear="all">
<div>
<p><span class="font5" style="font-weight:bold;">CHINAX</span></p>
<p><span class="font5" style="font-weight:bold;">CONNECT</span></p>
</div><br clear="all">
<p><span class="font10" style="font-weight:bold;">We assume coverage of Sinopharm (1099.HK) with a Neutral rating and Dec-17 PT of HKS44.0 </span><span class="font10">from a Not Rated designation (OW rating and $44 price target prior to NR designation). As the largest Chinese pharmaceutical distributor with the highest market cap, ample liquidity and a proven track record, we believe Sinopharm will continue to outgrow the industry average with its increasing market consolidation, margin expansion from improving operational leverage and further upside from new initiatives. Yet, Sinopharm has outperformed the MS CI healthcare index by 30% YTD, trading at 19x 2017E, vs its 17% EPS CAGR in 2015-2018E; we believe its growth potential is largely priced in. We advise investors to wait for a better entry point.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Dominant market share with sustainable above-industry growth: </span><span class="font10">Sinopharm led the pharmaceutical distribution industry with the largest market share of 18.4% in 2015 (source China Association of Pharmaceutical Commerce), up from merely 4.4% in 2003. It has consistently delivered above-industry average growth by 3-5%, thanks its increasing economies of scale and continuous operational improvement.</span></p></li>
<li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Beneficiary of faster industry consolidation: </span><span class="font10">We believe recent government policies to streamline the supply chain by stricter GSP and two invoice systems will eliminate smaller distributors, which will likely foster faster market share for Sinopharm ahead.</span></p>
<div>
<p><span class="font4" style="font-weight:bold;">China Healthcare Isabella Y. Zhao, CFA <sup>AC </sup></span><span class="font3">(852) 2800-8534 </span><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font3">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font4" style="font-weight:bold;">Joanne Cheung </span><span class="font3">(852) 2800-8596 </span><a href="mailto:joanne.cy.cheung@jpmorgan.com"><span class="font3">joanne.cy.cheung@jpmorgan.com</span></a><span class="font3"> J.P. Morgan Securities (Asia Pacific) Limited</span></p>
</div><br clear="all">
<div>
<p><span class="font2" style="font-weight:bold;">Price Performance</span></p>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<p><span class="font2">YTD &nbsp;&nbsp;&nbsp;&nbsp;Im &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3m &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12m</span></p>
<p><span class="font2">Abs </span><span class="font3">I </span><span class="font2">34.3% &nbsp;&nbsp;45% &nbsp;&nbsp;&nbsp;85% &nbsp;&nbsp;&nbsp;51.3%</span></p>
<p><span class="font2">Rei &nbsp;I 28.8% &nbsp;&nbsp;&nbsp;-1.8% &nbsp;&nbsp;&nbsp;&nbsp;-1.5% &nbsp;&nbsp;&nbsp;&nbsp;35.5%</span></p>
</div><br clear="all"></li>
<li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Multiple catalysts ahead: </span><span class="font10">We see further potential upside from recent initiatives such as: 1) e-commerce with 020 platform; 2) financial leasing 3) retail pharmacies expansion; and 4) management incentive on going SOE reform. All offer long-term earnings growth potential, in our view.</span></p></li>
<li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Risks: </span><span class="font10">1) unexpected industry slowdown; 2) margin contraction on harsh price cuts from government; 3) higher finance cost.</span></p></li></ul>
<p><span class="font4" style="font-weight:bold;text-decoration:underline;">Sinopharm (Reuters: 1099.HK, Bloomberg: 1099 HK)</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Rmb in mn, year-end Dec</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY13A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY14A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY15A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY16E</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY17E</span></p></td><td colspan="2" style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Company Data</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Revenue (Rmb mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">166,866</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">200,131</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">227,069</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">257,447</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">291,236</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">Shares O/S (mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,850</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Net Profit (Rmb mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,250</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,875</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">3,761</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">4,755</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">5,232</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">Market Cap (Rmb mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">99,555</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EPS (Rmb)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.89</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.11</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.36</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.67</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.84</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Market Cap ($ mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14,902</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">DPS (Rmb)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.25</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.26</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.31</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.38</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.42</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Price (HK$)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">40.55</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Revenue growth (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">22.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">19.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.4%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.1%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Date Of Price</span></p></td><td style="vertical-align:top;">
<p><span class="font2">05 Sep 16</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EPS growth (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">8.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">24.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">22.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">22.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">10.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Free FI oat (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">ROCE</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.8%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.6%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">12.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.3%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3M - Avg daily vol (mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font3">3.87</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">ROE</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.1%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.6%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3M - Avg </span><span class="font4" style="font-weight:bold;">daily val (HK$ mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">147.24</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">P/E (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">39.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2">31.4</span></p></td><td style="vertical-align:top;">
<p><span class="font2">25.7</span></p></td><td style="vertical-align:top;">
<p><span class="font2">20.9</span></p></td><td style="vertical-align:top;">
<p><span class="font2">19.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3M - Avg daily val ($ mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">19.0</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">P/BV (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">4.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3.3</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2.6</span></p></td><td style="vertical-align:top;">
<p><span class="font2">MSCICNX-HLTH</span></p></td><td style="vertical-align:top;">
<p><span class="font2">146.86</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EV/EBITDA (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">16.6</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.5</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2">10.4</span></p></td><td style="vertical-align:top;">
<p><span class="font2">9.3</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Exchange Rate</span></p></td><td style="vertical-align:top;">
<p><span class="font2">7.76</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Dividend Yield</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.1%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Price Target End Date</span></p></td><td style="vertical-align:top;">
<p><span class="font2">31-Dec-17</span></p></td></tr>
</table>
<p><span class="font2">Source: Company data, Bloomberg, J.P. Morgan estimates.</span></p>
<p><span class="font4" style="font-weight:bold;">See page 27 for analyst certification and important disclosures, including non-US analyst disclosures.</span></p>
<p><span class="font10">J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.</span></p>
<p><a href="http://www.jpmorganmarkets.com"><span class="font6">www.jpmorganmarkets.com</span></a></p>
</body>
</html>